Biodesix receives CE Mark for diagnostic kit

BOULDER – Biotech research company Biodesix Inc. on Wednesday announced that its VeriStrat specimen collection kit has obtained the CE Mark, paving the way for the company to make VeriStrat results available to doctors in the European Union and other countries that recognize the CE Mark.

VeriStrat is a noninvasive diagnostic test that predicts whether patients with non-operable, advanced non-small cell lung cancer would be better served by chemotherapy or the drug erlotinib.

The VeriStrat results are used along with other factors to guide treatment decisions.

VeriStrat, according to a Biodesix press release, will help doctors consider ruling out the roughly…